Arrowhead CFO Ken Myszkowski to retire May 13; Daniel Apel named successor
Arrowhead Pharmaceuticals said CFO Ken Myszkowski will retire effective May 13, 2025, after serving as CFO since 2009, and will stay on as an employee adviser through January 31, 2026. Daniel Apel, formerly Global Head of Financial Planning and Analysis at Walgreens Boots Alliance, will succeed him as CFO. The company describes the retirement as not the result of any disagreement.
Key points
- Ken Myszkowski retires as CFO effective May 13, 2025; he has served as CFO since 2009
- Daniel Apel appointed CFO; target bonus set at 45% of base salary
- Apel to receive a one-time grant of 100,000 restricted stock units vesting annually over four years, plus up to $200,000 in relocation benefits
- Myszkowski's transition adviser role runs until January 31, 2026, at a $200,000 annual base salary
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 15, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.